



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

June 3, 2021



Daily Change in COVID-19 Cases, US

January 22, 2020 – June 01, 2021

TOTAL Cases Reported Since 1/22/20

33,113,930

NEW Cases Reported to CDC on 6/1/21

9,358

Change in 7-Day Case Average


-30.8%

Current 7-Day Case Average (5/26/21 - 6/1/21)

15,623

Prior 7-Day Case Average (5/19/21 - 5/25/21)

22,567



New Admissions of Patients with Confirmed COVID-19, US

August 1, 2020 – May 31, 2021

Patients Currently Hospitalized with COVID on 5/31/21

17,910

New Admissions on 5/31/21

2,269

Peak in New Admissions (1/5/21)

17,963

Change in 7-Day Average of New Admissions


-13.8%

Current 7-Day Average of New Admissions (5/25/21 - 5/31/21)

2,743

Prior 7-Day Average of New Admissions (5/18/21 - 5/24/21)

3,182



Daily Change in COVID-19 Deaths, US

January 22, 2020 – June 01, 2021

TOTAL Deaths Reported Since 1/22/2020

592,232

NEW Deaths Reported to CDC on 6/1/21

431

Change in 7-Day Death Average

-16.6%

Current 7-Day Death Average (5/26/21 - 6/1/21)


363

Prior 7-Day Death Average (5/19/21 - 5/25/21)

436

Forecasted Total Deaths by 6/26/21

601,000 to 614,000



● New Deaths — 7-Day Moving Average - New Deaths*

*7-day averages exclude historical cases reported retroactively by states



Selected COVID-19 Therapeutics

Targeting the virus

- Remdesivir – FDA approved
- Other antivirals – clinical trials
- Anti-SARS-CoV-2 monoclonal antibodies – EUA
 - Regeneron (casirivimab + imdevimab)
 - Eli Lilly (bamlanivimab + etesevimab)
 - GSK & Vir (sotrovimab)
- Convalescent plasma – EUA



Moderating host responses

- Dexamethasone – recommended for hospitalized patients on oxygen
- Tocilizumab (with dexamethasone) – recommended for certain patients
- Baricitinib – EUA (with remdesivir)
- Other immunomodulators – clinical trials

Adjunctive therapeutics

- Anticoagulants – clinical trials

Selected COVID-19 Therapeutics

Targeting the virus

- Remdesivir – FDA approved
- Other antivirals – clinical trials
- Anti-SARS-CoV-2 monoclonal antibodies – EUA
 - Regeneron (casirivimab + imdevimab)
 - Eli Lilly (bamlanivimab + etesevimab)
 - GSK & Vir (sotrovimab)
- Convalescent plasma – EUA



Moderating host responses

- Dexamethasone – recommended for hospitalized patients on oxygen
- Tocilizumab (with dexamethasone) – recommended for certain patients
- Baricitinib – EUA (with remdesivir)
- Other immunomodulators – clinical trials

Adjunctive therapeutics

- Anticoagulants – clinical trials

Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab

A Gupta, A Shapiro et al.

- Randomized, placebo-controlled Phase 3 trial of non-hospitalized patients with mild-to-moderate COVID-19 at high risk for disease progression; total n= 583
- Single 500 mg dose of sotrovimab (GSK & Vir Biotechnology) reduced the risk of hospitalization or death by 85% compared with placebo
- Well tolerated; no safety signals identified
- *In vitro*, sotrovimab retains activity against multiple SARS-CoV-2 variants



U.S. Department of Health & Human Services



U.S. Food and Drug Administration
Protecting and Promoting Your Health

News Release

May 26, 2021

Coronavirus (COVID-19) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19

Emergency Use Authorization (EUA) issued for sotrovimab for treatment of mild-to-moderate COVID-19 in adult and pediatric patients (12 years and older; weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19.





THE WHITE HOUSE
WASHINGTON

WH.GOV